NASDAQ:SNOA Sonoma Pharmaceuticals (SNOA) Stock Price, News & Analysis $1.25 -0.03 (-2.34%) As of 09/21/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOwnershipSEC Filings About Sonoma Pharmaceuticals Stock (NASDAQ:SNOA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sonoma Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.25▼$1.2850-Day Range$1.10▼$1.4452-Week Range$0.85▼$4.60Volume27,523 shsAverage Volume57,212 shsMarket Capitalization$5.99 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Sonoma Pharmaceuticals, Inc. develops and commercializes non-antibiotic, non-steroidal products for wound care, dermatology, eye care, oral care and animal health. Its products are based largely on Microcyn technology, a stabilized hypochlorous-acid formulation designed for use in cleansing, managing and protecting damaged or irritated tissue. The company’s product portfolio has included wound cleansers and gels, dermatological treatments, scar-care products, ophthalmic solutions and veterinary products marketed under brands such as Microcyn, Dermacyn, Celacyn and MicrocynAH. These products are intended for applications including wound management, skin conditions, post-procedure care, eye discomfort and animal wound care. Sonoma Pharmaceuticals sells its products through distributors, commercial partners and other channels in the United States and selected international markets. The company was formerly known as Oculus Innovative Sciences and adopted the Sonoma Pharmaceuticals name in 2016.AI Generated. May Contain Errors. Read More Sonoma Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreSNOA MarketRank™: Sonoma Pharmaceuticals scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingSonoma Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageSonoma Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Sonoma Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Sonoma Pharmaceuticals is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sonoma Pharmaceuticals is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSonoma Pharmaceuticals has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Sonoma Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.85% of the float of Sonoma Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSonoma Pharmaceuticals has a short interest ratio ("days to cover") of 2.36, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sonoma Pharmaceuticals has recently decreased by 9.32%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSonoma Pharmaceuticals does not currently pay a dividend.Dividend GrowthSonoma Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 1 people have searched for SNOA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Sonoma Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sonoma Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders1.02% of the stock of Sonoma Pharmaceuticals is held by insiders.Percentage Held by Institutions1.95% of the stock of Sonoma Pharmaceuticals is held by institutions.Read more about Sonoma Pharmaceuticals' insider trading history. Receive SNOA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sonoma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNOA Stock News HeadlinesSonoma Pharmaceuticals Cancels Adjourned Special Stockholder MeetingAugust 19, 2026 | tipranks.comSonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly RevenueAugust 6, 2026 | benzinga.comA councilman backed AI — then 13 bullets hit his front doorThirteen bullets hit an Indianapolis councilman's front door days after he backed a data center rezoning. Across the country, protests, lawsuits, and moratoria are targeting AI infrastructure projects. Whitney Tilson, former hedge fund manager and editor of Stansberry's Investment Advisory, says November 4 could bring this conflict to a head, with major implications for investors' portfolios. | Stansberry Research (Ad)Sonoma Pharmaceuticals Expands At-the-Market Equity Offering CapacityJune 18, 2026 | tipranks.comSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial ResultsJune 16, 2026 | finanznachrichten.deWhat's going on with Sonoma Pharma stock Monday?April 27, 2026 | msn.comSonoma Pharmaceuticals Announces Pricing of $4 Million Public OfferingApril 25, 2026 | finance.yahoo.comSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and WalmartMarch 24, 2026 | finanznachrichten.deSee More Headlines SNOA Stock Analysis - Frequently Asked Questions How have SNOA shares performed this year? Sonoma Pharmaceuticals' stock was trading at $3.64 on January 1st, 2026. Since then, SNOA shares have decreased by 65.7% and is now trading at $1.25. How were Sonoma Pharmaceuticals' earnings last quarter? Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) announced its earnings results on Thursday, August, 6th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.32. The company earned $6.41 million during the quarter, compared to analysts' expectations of $4.99 million. Sonoma Pharmaceuticals had a negative trailing twelve-month return on equity of 21.41% and a negative net margin of 10.33%. How do I buy shares of Sonoma Pharmaceuticals? Shares of SNOA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sonoma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sonoma Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Meta Platforms (META), NVIDIA (NVDA), Bristol Myers Squibb (BMY), Advanced Micro Devices (AMD), Ford Motor (F) and PayPal (PYPL). Company Calendar Last Earnings8/06/2026Today9/21/2026Next Earnings (Estimated)11/16/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 SNOA's financial health is in the Red zone, according to TradeSmith. SNOA has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SNOA CIK1367083 Webwww.sonomapharma.com Phone(800) 759-9305Fax707-283-0551Employees260Year Founded1999Profitability EPS (Trailing Twelve Months)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.17 million Net Margins-10.33% Pretax Margin-11.44% Return on Equity-21.41% Return on Assets-6.08% Debt Debt-to-Equity RatioN/A Current Ratio2.99 Quick Ratio2.29 Sales & Book Value Annual Sales$19.53 million Price / Sales0.31 Cash FlowN/A Price / Cash FlowN/A Book Value$0.65 per share Price / Book1.92Miscellaneous Outstanding Shares4,790,000Free Float4,739,000Market Cap$5.99 million OptionableNot Optionable Beta1.31 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:SNOA) was last updated on 9/22/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredA councilman backed AI — then 13 bullets hit his front doorThirteen bullets hit an Indianapolis councilman's front door days after he backed a data center rezoning. Acro...Stansberry Research | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | Sponsored“Elon Is Not Showing This Publicly, But I Saw It”Elon Musk quietly filed a patent for a new AI invention while attention focused on the SpaceX IPO. Jeff Brown,...Brownstone Research | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredGold did this exact thing in 1975… [then exploded]In 1975 the Fed raised rates and gold fell 50 percent. Headlines called the gold bull market dead. Instead gol...Golden Portfolio | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
